Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Pfizer Inc.

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

June 28, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

June 25, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts

June 24, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Declares Third-Quarter 2022 Dividend

June 23, 2022

From Pfizer Inc.

Via Business Wire

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

June 20, 2022

From Pfizer Inc.

Via Business Wire

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

June 17, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA

June 14, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Completes Acquisition of ReViral

June 09, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

June 09, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

June 08, 2022

From Pfizer Inc.

Via Business Wire

Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.

June 06, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer

June 04, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Provides Update on Ownership Interest in Haleon

June 01, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability

May 31, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

May 26, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 25, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries

May 25, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis

May 24, 2022

From Pfizer Inc.

Via Business Wire

Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose

May 23, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age

May 17, 2022

From Pfizer Inc.

Via Business Wire

Pfizer to Acquire Biohaven Pharmaceuticals

May 10, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Reports First-Quarter 2022 Results

May 03, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Declares Second-Quarter 2022 Dividend

April 28, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine

April 27, 2022

From Pfizer Inc.

Via Business Wire

Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

April 26, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28

April 19, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

April 14, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Names David M. Denton Chief Financial Officer

April 11, 2022

From Pfizer Inc.

Via Business Wire

Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

April 07, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older

March 29, 2022

From Pfizer Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.